Peronace Cinzia, Tallerico Rossana, Colosimo Manuela, Fazio Marco De, Pasceri Federica, Talotta Ilenia, Panduri Giuseppina, Pintomalli Letizia, Oteri Rosaria, Calantoni Valeria, Fiorillo Maria Teresa, Caroleo Maria Cristina, Curcio Rosita, Dolce Vincenza, Cione Erika, Minchella Pasquale
Microbiology and Virology Unit, Pugliese-Ciaccio Hospital, 88100 Catanzaro, Italy.
Unit of Microbiology and Virology, North Health Center ASP 5, 89123 Reggio Calabria, Italy.
Biomedicines. 2022 Jul 30;10(8):1839. doi: 10.3390/biomedicines10081839.
The rapid emergence and worldwide detection of the SARS-CoV-2 Omicron variant underscore the importance of robust genomic surveillance systems and prompt information sharing among global public health partners. The Omicron variant has rapidly replaced the Delta variant as a dominating SARS-CoV-2 variant because of natural selection, favoring the variant with higher infectivity and stronger vaccine breakthrough capability. The Omicron variant is also known as B.1.1.529. It has four sub-variants, indicated as BA.1, BA.2, BA.3 and BA.4. Among them, BA.1 is the currently prevailing sub-variant, and BA.2 has been found to be able to alarmingly re-infect patients initially infected by Omicron BA.1. The BA.3 sub-variant is a combination of mutations of BA.1 and BA.2, especially in the spike protein. Today, the BA.4 variant is emerging, which is herein described, and it was the first detected in Italy. Via bioinformatic analysis, we are reporting that the BA.4 that was identified harbors a new mutation, specifically a deletion in the ORF1ab gene, corresponding to KSF141_del in non-structural protein 1 (nsp1), a critical virulence factor able to suppress host translation. The bioinformatics comparison analysis with the other three sub-variants reveals that the deletion was not present before and was never reported until now. Therefore, we can speculate that Omicron BA.4 will become a new dominating "variant of concern" and may also break vaccine protection. Moreover, we show that other proteins are mutated in the BA.4. In particular, seven mutations are recognized in the nucleocapsid (N) protein, and the capability of five different types of rapid antigenic tests are used to identify it.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)奥密克戎变种的迅速出现及在全球范围内被检测到,凸显了强大的基因组监测系统以及全球公共卫生伙伴之间及时信息共享的重要性。由于自然选择青睐具有更高传染性和更强疫苗突破能力的变种,奥密克戎变种已迅速取代德尔塔变种,成为主要的SARS-CoV-2变种。奥密克戎变种也被称为B.1.1.529。它有四个亚变种,分别为BA.1、BA.2、BA.3和BA.4。其中,BA.1是目前流行的亚变种,并且已发现BA.2能够惊人地再次感染最初感染奥密克戎BA.1的患者。BA.3亚变种是BA.1和BA.2突变的组合,特别是在刺突蛋白方面。如今,BA.4变种正在出现,本文将对其进行描述,它首次在意大利被检测到。通过生物信息学分析,我们报告所鉴定的BA.4存在一个新突变,具体为开放阅读框1ab(ORF1ab)基因中的一个缺失,对应于非结构蛋白1(nsp1)中的KSF141_del,nsp1是一种能够抑制宿主翻译的关键毒力因子。与其他三个亚变种的生物信息学比较分析表明,该缺失以前不存在,迄今为止也从未有过报道。因此,我们可以推测奥密克戎BA.4将成为一个新的主要“关注变种”,并且可能也会突破疫苗防护。此外,我们表明BA.4中的其他蛋白质也发生了突变。特别是,在核衣壳(N)蛋白中识别出七个突变,并使用五种不同类型的快速抗原检测方法对其进行鉴定。